Table 2.

Demographics, tumor characteristics, and clinical outcomes by PTEN status

MeasurePTEN absent (N = 31)PTEN not absent (N = 93)P
Gender, n (%)
 Male22 (71)63 (68)0.826a
 Female9 (29)30 (32)
Age at stage III diagnosis (y), median (range)48 (26.3–82.4)58.1 (24.9–85.4)0.073b
Clinical/pathologic type, n (%)
 Acral4 (13)12 (13)0.878a
 Cutaneous20 (65)65 (70)
 Mucosal1 (3)3 (3)
 Unknown primary6 (19)13 (14)
Breslow thickness (mm), median (range)3.2 (0.4–25.0)3.2 (0.3–33.0)0.462b
Ulceration, n (%)
 No6 (30)10 (15)0.188a
 Yes14 (70)56 (85)
 Missing1127
Time to any recurrence (y), median (95% CI)0.7 (0.5–1.1)0.7 (0.5–0.9)0.913c
Time to any distant recurrence (y), median (95% CI)0.9 (0.6–1.4)1.2 (0.7–1.7)0.352c
OS (y), median (95% CI)1.9 (1.5–2.1)3.1 (2.0–4.1)0.031c
Time to CNS metastasis (y), median (95% CI)1.8 (1.2–2.5)4.9 (2.4, NE)0.030c
Time to lung metastasis (y), median (95% CI)2.1 (1.1, NE)3.3 (1.9–6.1)0.920c
Time to liver metastasis (y), median (95% CI)NE (1.4, NE)6.3 (3.0, NE)0.522c
Time to bone metastasis (y), median (95% CI)NE (1.4, NE)NE (6.3, NE)0.102c

Abbreviations: CI, confidence interval; NE, not estimated.

  • aFisher exact test.

  • bWilcoxon rank-sum test.

  • cLog-rank test.